Clinical trials: Leukemia/Lymphoma
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
- Conditions
- B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05281809
- Testing
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- John Lister
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
INCB018424 in Patients With Advanced Hematologic Malignancies
The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT00674479
- Testing
- INCB018424
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Leukaemia (Acute), Acute Lymphoblastic Leukemia
Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia
This current study will implement a proposed whole program of monitoring and prevention acute hepatic injury during the time of induction chemotherapy in children and adolescent with ALL.
- Trial name
- NCT06918054
- Testing
- Dietary modification, Supplementation of omega 3 fatty acids
- Where
- 2 sites in Egypt
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT03467256
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Fludarabine, Cyclophosphamide
- Where
- Russia
- Volunteers
- 18 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
- Trial name
- NCT07071051
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Leukemia, Acute Lymphocytic Leukemia
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
The goal of Phase I of this clinical research study is to find the highest tolerable dose of RAD001 (everolimus) when given in combination with the standard chemotherapy regimens to patients with ALL.
- Trial name
- NCT00968253
- Testing
- Everolimus (RAD001), Cyclophosphamide, Vincristine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse
Yoga Fatigue Study
Fatigue is a major problem in children, adolescents and adults receiving intensive chemotherapy for cancer and in patients undergoing hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse, Burkitt's Lymphoma Stage III, Burkitt's Lymphoma Stage IV
- Trial name
- NCT02134782
- Testing
- Individualized Yoga Intervention Group, iPad Activity Control Group
- Where
- 3 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- The Hospital for Sick Children
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This is a Phase II, open label, fixed dose, repeat injection, single institution study. Eligible subjects will receive up to six doses of Ad-ISF35 injected directly into a selected lymph node under ultrasound guidance.
- Trial name
- NCT00849524
- Testing
- ISF35
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Januario Castro, M.D.
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
This study aims to investigate the role of extracellular vesicles as diagnosic and prognostic biomarkers in patients with lymphomas or lymphoproliferative disorders.
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma(MZL), Mycosis Fungoides
- Trial name
- NCT06782854
- Where
- Italy
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a…
- Trial name
- NCT07221500
- Testing
- NX-5948
- Where
- 43 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Nurix Therapeutics, Inc.
COVID-19, Pediatric ALL
Symptom Patterns and Life With Longer Term COVID-19 in Children and Young People (SPLaT-19 Cohort & Qualitative Study)
Introduction: While there is a substantial body of knowledge about acute Covid-19 in children and young people (CYP), less is known about long-COVID, where symptoms continue beyond four weeks, particularly since the most recent…
- Trial name
- SPLaT-19 (NCT05422937)
- Where
- United Kingdom
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Keele University
Leukemia, Lymphoma
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B-cell derived malignancies.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT02954445
- Testing
- Anti-BCMA-CAR-transduced T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Southwest Hospital, China
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Acute Lymphoblastic Leukemia
Effects of Home-Based Exercise Program in Children After Acute Lymphoblastic Leukemia
This prospective randomized controlled study aimed to investigate the effects of a home-based exercise program on physical functions, inflammatory markers, and Brain-Derived Neurotrophic Factor (BDNF) in children followed after…
- Trial name
- NCT06664736
- Testing
- Exercise, Physical activity
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Gazi University
Acute Lymphoblastic Leukemia
ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate
In phase 2 and phase 3 studies, inotuzumab has shown evidence of single agent anti-leukemic activity and proved to be particularly effective in providing a deep response, with an acceptable safety profile.
- Trial name
- INO-CD22 (NCT03898128)
- Testing
- Anti-CD22 Immunotoxin
- Where
- 5 sites in Italy
- Volunteers
- 84 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL)
A Multi-center Retrospective Study of INO Treating B-ALL
This multi-center retrospective study aims to evaluate the efficacy and safety of inotuzumab ozogamicin in adults B-ALL of different subgroups. This study is a retrospective study.
- Conditions
- Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin, Venetoclax
- Trial name
- NCT07238907
- Testing
- Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Ruijin Hospital
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma.
- Trial name
- NCT00669877
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Ublituximab + Ibrutinib in Select B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
- Trial name
- NCT02013128
- Testing
- Ublituximab, Ibrutinib
- Where
- 18 sites in United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined…
- Trial name
- NCT06051409
- Testing
- Olverembatinib, Investigator's choice of TKI
- Where
- 90 sites in United States, Australia and 10 more
- Volunteers
- 350 people
- Sponsor
- Ascentage Pharma Group Inc.
Philadelphia Chromosome, Acute Myeloid Leukemia
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The purpose of this study is to evaluate the efficacy and safety of azacitidine，venetoclax，and flumatinib in newly diagnosed Philadelphia chromosome-positive acute leukemia and accelerated phase or blast phase chronic myeloid…
- Conditions
- Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT05433532
- Testing
- Azacitidine, Venetoclax, Flumatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.